Piedmont Investment Advisors Inc. bought a new position in shares of ICU Medical, Incorporated (NASDAQ:ICUI) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,129 shares of the medical instruments supplier’s stock, valued at approximately $319,000.
A number of other large investors have also recently added to or reduced their stakes in the business. Cerebellum GP LLC bought a new stake in shares of ICU Medical in the 3rd quarter worth approximately $186,000. Mackay Shields LLC bought a new stake in shares of ICU Medical in the 2nd quarter worth approximately $205,000. CIBC Asset Management Inc bought a new stake in shares of ICU Medical in the 2nd quarter worth approximately $209,000. MML Investors Services LLC bought a new stake in shares of ICU Medical in the 3rd quarter worth approximately $217,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of ICU Medical in the 2nd quarter worth approximately $235,000. 74.49% of the stock is currently owned by institutional investors.
In related news, VP Virginia Ruth Sanzone sold 787 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $303.12, for a total value of $238,555.44. Following the sale, the vice president now directly owns 1,367 shares in the company, valued at approximately $414,365.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Pfizer Inc sold 2,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $209.25, for a total value of $523,125,000.00. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.
ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 8th. The medical instruments supplier reported $1.85 EPS for the quarter, beating the consensus estimate of $1.51 by $0.34. ICU Medical had a return on equity of 15.20% and a net margin of 6.00%. The firm had revenue of $327.20 million for the quarter, compared to analysts’ expectations of $334.97 million. During the same period last year, the firm earned $1.12 EPS. The firm’s revenue was down 4.7% compared to the same quarter last year. Equities analysts anticipate that ICU Medical, Incorporated will post 7.76 earnings per share for the current year.
Several brokerages recently issued reports on ICUI. Zacks Investment Research raised ICU Medical from a “hold” rating to a “strong-buy” rating and set a $297.00 price target on the stock in a report on Thursday, November 1st. ValuEngine downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. BidaskClub downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. Finally, TheStreet raised ICU Medical from a “c+” rating to a “b+” rating in a report on Monday, August 20th.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
See Also: Depreciation
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Incorporated (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.